secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264693
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q3 revenue $19.6M, net loss $31.7M; restructuring targets $40M savings
--------------------------------------------------------------------------------

- Revenue from continuing ops $19.6M, down 11% YoY; net loss $31.7M vs $21.9M loss in Q3 2024.
- Adjusted EBITDA loss $16.5M vs $13.7M loss; restructuring plan cuts ~20% workforce for $40M annual savings.
- Cash $217M at Sept 30; expects ~$550M cash at close of Illumina transaction in H1 2026.
- FY2025 revenue guidance reaffirmed: combined $165-175M, continuing ops $78-83M.
- Gross margin 48.5% (GAAP) and 53.5% (non-GAAP), down from prior year due to volume and mix.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/0001193125-25-264693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/lab-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer